臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :2853327
	造访人次 : 45007083 在线人数 : 1556 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lu l c"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-10 / 144 (共15页)
1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-09-15T01:08:47Z	Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites	Guo J.-C.; Lin C.-Y.; Chia-Chi Lin; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H.
臺大學術典藏	2022-09-14T01:29:23Z	Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy	Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L.
臺大學術典藏	2022-08-23T02:35:03Z	Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience	Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏	2022-08-19T06:48:44Z	Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites	Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU
臺大學術典藏	2022-08-19T00:20:55Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shen Y.-C.; Hsu C.-H.; Cheng A.-L.; CHIUN HSU; Lin Z.-Z.; Lu L.-C.; Shao Y.-Y.
臺大學術典藏	2022-08-19T00:20:38Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Liu T.-H.; Shao Y.-Y.; Lu L.-C.
臺大學術典藏	2022-08-19T00:20:36Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; CHIUN HSU; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2022-08-19T00:20:26Z	Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy	CHIUN HSU; Shao Y.-Y.; Chen C.-H.; Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.-H.; Lin Z.-Z.; Lu L.-C.; Liu T.-H.; Cheng A.-L.
臺大學術典藏	2022-08-19T00:20:25Z	Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma	Liang P.-C.; Liu T.-H.; Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chen B.-B.; Shih T.T.-F.; Shen Y.-C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:07Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.

显示项目 1-10 / 144 (共15页)
1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目